A
Ana Espinel-Ingroff
Researcher at VCU Medical Center
Publications - 166
Citations - 13837
Ana Espinel-Ingroff is an academic researcher from VCU Medical Center. The author has contributed to research in topics: Broth microdilution & Posaconazole. The author has an hindex of 63, co-authored 165 publications receiving 13039 citations. Previous affiliations of Ana Espinel-Ingroff include Virginia Commonwealth University.
Papers
More filters
Journal ArticleDOI
Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections
John H. Rex,Michael A. Pfaller,John N. Galgiani,Marilyn S. Bartlett,Ana Espinel-Ingroff,Mahmoud A. Ghannoum,M Lancaster,Frank C. Odds,Michael G. Rinaldi,Thomas J. Walsh,A L Barry +10 more
TL;DR: The conceptual framework underlying interpretation of antimicrobial susceptibility testing results is examined and these ideas are used to drive analysis of data packages developed by the respective manufacturers that correlate fluconazole and itraconazole MICs with outcome of candidal infections.
Journal ArticleDOI
Voriconazole Treatment for Less-Common, Emerging, or Refractory Fungal Infections
John R. Perfect,Kieren A. Marr,Thomas J. Walsh,Richard N. Greenberg,Bertrand Dupont,Julián Torre-Cisneros,Gudrun Just-Nübling,Haran T. Schlamm,Irja Lutsar,Ana Espinel-Ingroff,Elizabeth M. Johnson +10 more
TL;DR: Voriconazole is an effective and well-tolerated treatment for refractory or less-common invasive fungal infections and as primary treatment for patients with infections for which there is no approved therapy.
Journal ArticleDOI
Comparison of In Vitro Activities of the New Triazole SCH56592 and the Echinocandins MK-0991 (L-743,872) and LY303366 against Opportunistic Filamentous and Dimorphic Fungi and Yeasts
TL;DR: The in vitro antifungal activities of SCH56592, MK-0991, and LY303366 suggest that these new agents have broad-spectrum activities in vitro; their effectiveness in the treatment of human mycoses is to be determined.
Journal ArticleDOI
Antifungal Susceptibility Testing: Practical Aspects and Current Challenges
John H. Rex,Michael A. Pfaller,Thomas J. Walsh,Vishnu Chaturvedi,Ana Espinel-Ingroff,Mahmoud A. Ghannoum,Linda L. Gosey,Frank C. Odds,Michael G. Rinaldi,Daniel J. Sheehan,David W. Warnock +10 more
TL;DR: Reference methods for yeasts and molds (NCCLS M27-A and M38-P) are now available and Clinically relevant testing is now available for selected fungi and drugs.
Journal ArticleDOI
In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
TL;DR: The in vitro activities of voriconazole were similar to or better than those of itraconazole and amphotericin B against Aspergillus spp, Fusarium spp.